Literature DB >> 7498228

Simultaneous administration of 111In-human immunoglobulin and 99mTc-HMPAO labelled leucocytes in inflammatory bowel disease.

L Mairal1, P A de Lima, J Martin-Comin, C Baliellas, X Xiol, M Roca, Y Ricart, M Ramos.   

Abstract

Technetium-99m hexamethylpropylene amine oxime (HMPAO) labelled leucocytes and indium-111 polyclonal immunoglobulin (IgG) were simultaneously injected into a group of 27 patients routinely referred for the investigation of inflammatory bowel disease (IBD). Ten-minute anterior abdomen and tail on detector views were obtained at 30 min, 4 h and 24 h p.i. of both tracers. The diagnosis of IBD was obtained in all cases by endoscopy with biopsy and/or surgery. Images were blindly evaluated by two experienced observers who only knew of the clinical suspicion of IBD. IBD was confirmed in 20 patients (12 with Crohn's disease and eight with ulcerative colitis). Sensitivity, specificity and accuracy were 100%, 85% and 96% respectively for labelled leucocytes and 70%, 85% and 74% for IgG. Both IgG and leucocyte scans were normal in six out of seven patients in whom a diagnosis of IBD was excluded; the remaining patient, with ischaemic colitis, was falsely positive with both agents. As far as disease extension is concerned, the IgG study localized 27 diseased segments, whereas 49 were seen with the leucocyte study. Eighty-four segments were normal and 25 showed tracer uptake with both agents. Twenty-four were positive only with the leucocyte study and two were positive only with the IgG study. Agreement between the agents was 80.7%. These results confirm that 111In-human polyclonal scintigraphy is less sensitive than 99mTc-HMPAO scintigraphy both for the diagnosis of IBD and in the evaluation of disease extension. Nevertheless, if leucocyte labelling is not available, labelled IgG can be used only for diagnostic purposes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7498228     DOI: 10.1007/bf01254568

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  19 in total

1.  Imaging inflammation with human polyclonal immunoglobulin: not looked for but discovered.

Authors:  F H Corstens; R A Claessens
Journal:  Eur J Nucl Med       Date:  1992

2.  Diagnosis of bone, joint, and joint prosthesis infections with In-111-labeled nonspecific human immunoglobulin G scintigraphy.

Authors:  W J Oyen; J R van Horn; R A Claessens; T J Slooff; J W van der Meer; F H Corstens
Journal:  Radiology       Date:  1992-01       Impact factor: 11.105

3.  111In-oxine-labelled autologous leucocytes in inflammatory bowel disease: new scintigraphic activity index.

Authors:  A Ybern; J Martin-Comin; J J Giné; T Casanovas; R Villa; M A Gassull
Journal:  Eur J Nucl Med       Date:  1986

4.  Inflammation: imaging with Tc-99m HMPAO-labeled leukocytes.

Authors:  M E Roddie; A M Peters; H J Danpure; S Osman; B L Henderson; J P Lavender; M J Carroll; R D Neirinckx; J D Kelly
Journal:  Radiology       Date:  1988-03       Impact factor: 11.105

5.  Comparison of simultaneous 99mTc-HMPAO and 111In oxine labelled white cell scans in the assessment of inflammatory bowel disease.

Authors:  R A Allan; G E Sladen; S Bassingham; C Lazarus; S E Clarke; I Fogelman
Journal:  Eur J Nucl Med       Date:  1993-03

6.  A prospective comparison of 99mTc-labeled polyclonal human immunoglobulin and 111In granulocytes for localization of inflammatory bowel disease.

Authors:  J W Arndt; A van der Sluys Veer; D Blok; G Griffioen; H W Verspaget; A S Peña; C B Lamers; E K Pauwels
Journal:  Acta Radiol       Date:  1992-03       Impact factor: 1.990

7.  The efficacy of indium-111-polyclonal IgG for the detection of infection and inflammation.

Authors:  F L Datz; C E Anderson; R Ahluwalia; J H Whiting; F V Gabor; K A Morton; P E Christian; K Crebs; M Neptune; D A Rauh
Journal:  J Nucl Med       Date:  1994-01       Impact factor: 10.057

8.  Scintigraphic assessment of bowel involvement and disease activity in Crohn's disease using technetium 99m-hexamethyl propylene amine oxine as leukocyte label.

Authors:  J Schölmerich; E Schmidt; C Schümichen; P Billmann; H Schmidt; W Gerok
Journal:  Gastroenterology       Date:  1988-11       Impact factor: 22.682

9.  Prospective comparative study of technetium-99m-WBCs and indium-111-granulocytes for the examination of patients with inflammatory bowel disease.

Authors:  J W Arndt; A van der Sluys Veer; D Blok; G Griffoen; H W Verspaget; C B Lamers; E K Pauwels
Journal:  J Nucl Med       Date:  1993-07       Impact factor: 10.057

10.  The use of radiolabeled nonspecific immunoglobulin in the detection of focal inflammation.

Authors:  R H Rubin; A J Fischman
Journal:  Semin Nucl Med       Date:  1994-04       Impact factor: 4.446

View more
  5 in total

Review 1.  In vivo imaging of insulitis in autoimmune diabetes.

Authors:  A Signore; M Chianelli; M G Parisella; G Capriotti; P Giacalone; G Di Leve; R Barone
Journal:  J Endocrinol Invest       Date:  1999-02       Impact factor: 4.256

Review 2.  Role of scintigraphy in inflammatory bowel disease.

Authors:  Maria I Stathaki; Sophia I Koukouraki; Nikolaos S Karkavitsas; Ioannis E Koutroubakis
Journal:  World J Gastroenterol       Date:  2009-06-14       Impact factor: 5.742

3.  Visualising E-selectin in the detection and evaluation of inflammatory bowel disease.

Authors:  M Bhatti; P Chapman; M Peters; D Haskard; H J Hodgson
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

4.  Antimicrobial peptides as infection imaging agents: better than radiolabeled antibiotics.

Authors:  Muammad Saeed Akhtar; Muhammad Babar Imran; Muhammad Afzal Nadeem; Abubaker Shahid
Journal:  Int J Pept       Date:  2012-05-17

5.  The Usefulness of Scintigraphic Studies in the Assessment of Asymptomatic Bowel Disease in Patients with Primary Antibody Diseases.

Authors:  Cinzia Milito; Francesco Cinetto; Valentina Megna; Giuseppe Spadaro; Isabella Quinti; Mauro Liberatore
Journal:  J Clin Med       Date:  2020-03-30       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.